Qiagen N.V. (QGEN)
After hours:
| Previous close | 45.83 |
| Open | 45.95 |
| Bid | 35.04 x 800 |
| Ask | 53.00 x 900 |
| Day's range | 45.58 - 46.15 |
| 52-week range | 40.38 - 51.18 |
| Volume | |
| Avg. volume | 658,347 |
| Market cap | 10.509B |
| Beta (5Y monthly) | 0.39 |
| PE ratio (TTM) | 25.08 |
| EPS (TTM) | 1.84 |
| Earnings date | 24 Apr 2023 - 28 Apr 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 54.04 |
- Business Wire
QIAGEN Announces Form 20-F Annual Report Filing for 2022 Results
VENLO, The Netherlands, March 13, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2022, with the U.S. Securities and Exchange Commission. The document can be accessed on QIAGEN’s website here.
- Zacks
QIAGEN (QGEN) to Develop CDx Test for TIBSOVO With New Pact
QIAGEN (QGEN) will develop a real-time in vitro PCR test that can be utilized to spot IDH1 gene mutations in AML patients in whole blood and bone marrow aspirates.
- Business Wire
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy Drug
VENLO, the Netherlands, March 09, 2023--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced it has entered into a strategic partnership with Servier, a global pharmaceutical group, to develop a companion diagnostic test for TIBSOVO®, an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for the treatment of the blood cancer acute myeloid leukemia (AML).
